Miguel A. Carrillo-Martinez’s research while affiliated with Tecnológico de Monterrey and other places

Antecedentes: La insuficiencia venosa es un padecimiento frecuente que puede ser tratado mediante técnicas endovasculares, incluyendo la ablación endovenosa con láser. Objetivo: Evaluar las posibles complicaciones a corto plazo derivadas de la ablación endovenosa con láser para tratamiento de insuficiencia venosa en safena mayor y menor. Métodos: Se incluyeron 158 miembros inferiores con diagnóstico clínico y por ultrasonido Doppler de insuficiencia venosa superficial. Fueron sometidos a ablación endovenosa con láser 1470 nm y fibra radial (400 y 600 nm) de forma ambulatoria y el seguimiento postoperatorio se llevó a cabo entre 15-30 días posterior al tratamiento. Resultados: 32 sujetos (20%) presentaron complicaciones menores, las cuales fueron síndrome doloroso (10.7%), parestesia (6.3%), seroma (1.2%), hematoma (0.6%), equimosis sintomática (0.6%) y tromboflebitis superficial (1.2%). No se registraron complicaciones graves. Conclusiones: Nuestros resultados coinciden con lo reportado comúnmente en la literatura, sin registrar complicaciones graves, por lo que consideramos que la ablación endovenosa con láser es un procedimiento seguro.

Background: There is a lack of studies describing the normal size of the aorta in Mexican population. Objective: To analyze aortic measurements in Mexican patients and to compared them with patients from five different countries. Methods: Measurements of the aorta were divided in Mexicans and controls. Comparisons between ethnicities and groups were performed using Mann Whitney rank sum test. Results: The registry included 166 patients, 106 (63.8%) were enrolled in Mexico and 60 (36.1%) in the control group. Mexican patients had smaller aortic diameters compared to the control group, at the level of the right renal artery ostium, inferior mesenteric artery, and aortic bifurcation. The Hispanic population had significantly smaller aortic diameters from the level of the celiac artery to the aortic bifurcation. Conclusion: The normal aortic diameters in the Mexican population are smaller compared to other countries.

Introduction and aims Orthotopic liver transplant (OLT) is the definitive treatment of most types of liver failure. Transjugular intrahepatic portosystemic shunt (TIPS) and portocaval shunt placement procedures reduce the systemic vascular complications of portal hypertension. TIPS placement remains a “bridge” therapy that enables treatment of refractory symptoms until transplantation becomes available. The aim of the present study was to describe the operative impact of TIPS prior to OLT. Materials and methods A retrospective review was conducted on patients that underwent liver transplant at the Hospital San José within the timeframe of 1999 and February 2020. Results We reviewed a total of 92 patients with OLT. Sixty-six patients were male and 26 were female, with a mean age of 52 years. Nine (9.8%) of the 92 patients had a TIPS, before the OLT. Preoperative Child-Pugh class, MELD score, and sodium and platelet levels were similar between groups. We found no difference in the means of intensive care unit stay, operative time, or blood transfusions for liver transplant, with or without previous TIPS. There was no significant difference between groups regarding vascular and biliary complication rates or the need for early intervention. The overall one-year mortality rate in the TIPS group was 11%. Conclusions TIPS is an appropriate therapeutic bridge towards liver transplant. We found no greater operative or postoperative complications in patients with TIPS before OLT, when compared with OLT patients without TIPS. The need for transfusion, operative time, and ICU stay were similar in both groups.

Hepatocellular carcinoma (HCC) is more frequently manifesting as one of the main complications of cirrhosis of the liver, its principal risk factor. There have been modifications in its incidence over the past decade, related to an epidemiologic transition in the etiology of cirrhosis, with a decrease in the prevalence of hepatitis C and an increase in nonalcoholic fatty liver disease (NAFLD) as a cause, as well as the development of HCC in the non-cirrhotic liver due to NAFLD. Genetic markers associated with the disease have been identified, and surveillance and diagnosis have improved. Regarding treatment, surgical techniques, in both resection and transplantation, have advanced and radiologic techniques, at the curative stage of the disease, have enhanced survival in those patients. And finally, there have been radical changes in the systemic approach, with much more optimistic expectations, when compared with the options available a decade ago. Therefore, the Asociación Mexicana de Hepatología decided to carry out the Second Mexican Consensus on Hepatocellular Carcinoma, which is an updated review of the available national and international evidence on the epidemiology, risk factors, surveillance, diagnosis, and treatment of the disease, to offer the Mexican physician current information on the different topics regarding hepatocellular carcinoma. In this second part of the document, the topics related to the treatment of HCC are presented.

Resumen El carcinoma hepatocelular (CHC) se presenta cada vez más frecuentemente como una de las principales complicaciones de cirrosis, su principal factor de riesgo. La última década ha presentado modificaciones en su incidencia, relacionadas con una transición epidemiológica en la etiología de la cirrosis, con disminución en la prevalencia de hepatitis C y aumento en la etiología relacionada con la enfermedad por hígado graso no alcohólico (EHNA), además del desarrollo del CHC en hígado no cirrótico por EHNA. Se han identificado marcadores genéticos asociados a la enfermedad, así como avances en vigilancia y diagnóstico. Con relación al tratamiento, el perfeccionamiento de técnicas quirúrgicas, tanto relacionadas con la resección como con el trasplante, y radiológicas en estadios curativos permite mejorar la supervivencia de los pacientes candidatos a este abordaje, y, finalmente, hay cambios radicales en el abordaje sistémico con expectativas mucho más optimistas cuando se comparan con lo disponible hace una década. Es por eso que la Asociación Mexicana de Hepatología decidió realizar el II Consenso Mexicano de Carcinoma Hepatocelular, en el cual se hizo una revisión actualizada de la evidencia disponible nacional e internacional sobre la epidemiología, factores de riesgo, vigilancia, diagnóstico y tratamiento de la enfermedad; con el objetivo de ofrecer al médico mexicano una revisión actualizada sobre los diferentes tópicos de esta enfermedad. En esta segunda parte del documento se presentan los tópicos relacionados con el tratamiento del CHC.

Hepatocellular carcinoma (HCC) is more frequently manifesting as one of the main complications of cirrhosis of the liver, its principal risk factor. There have been modifications in its incidence over the past decade, related to an epidemiologic transition in the etiology of cirrhosis, with a decrease in the prevalence of hepatitis C and an increase in nonalcoholic fatty liver disease (NAFLD) as a cause, as well as the development of HCC in the non-cirrhotic liver due to NAFLD. Genetic markers associated with the disease have been identified, and surveillance and diagnosis have improved. Regarding treatment, surgical techniques, in both resection and transplantation, have advanced and radiologic techniques, at the curative stage of the disease, have enhanced survival in those patients. And finally, there have been radical changes in the systemic approach, with much more optimistic expectations, when compared with the options available a decade ago. Therefore, the Asociación Mexicana de Hepatología decided to carry out the Second Mexican Consensus on Hepatocellular Carcinoma, which is an updated review of the available national and international evidence on the epidemiology, risk factors, surveillance, diagnosis, and treatment of the disease, to offer the Mexican physician current information on the different topics regarding hepatocellular carcinoma. In this first part of the document, the topics related to epidemiology and diagnosis are presented.